Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  GenMark Diagnostics, Inc    GNMK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:31pm CET

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the GenMark investigation page on our website www.glancylaw.com/case/genmark-diagnostics-inc.

On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.

On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased GenMark securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENMARK DIAGNOSTICS, INC
01/09 GENMARK DIAGNOSTICS, INC. : Results of Operations and Financial Condition (form ..
01/09 GenMark Diagnostics Provides Preliminary Operational and Financial Results fo..
2017 GenMark Diagnostics to Present at the J.P. Morgan 36th Annual Healthcare Con..
2017 GENMARK DIAGNOSTICS, INC. : Entry into a Material Definitive Agreement, Creation..
2017 GNMK Law Offices of Howard G. Smith Continues Investigation on Behalf of GenM..
2017 GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of GenMark Diagn..
2017 GNMK Law Offices of Howard G. Smith Commences Investigation on Behalf of GenM..
2017 GENMARK DIAGNOSTICS : to Present at the Canaccord Genuity Medical Technologies &..
2017 GENMARK DIAGNOSTICS, INC : Bronstein, Gewirtz & Grossman, LLC Announces Investig..
2017 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of GenMark Diagn..
More news
News from SeekingAlpha
01/09 GenMark Diagnostics provides preliminary results for 2017
2017 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
2017 GenMark's Credibility Is Dented, But The Sell-Off Is Excessive
2017 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
2017 YOUR DAILY PHARMA SCOOP : Anxious Time For Dynavax Longs, VBL Therapeutics Gets ..
Financials ($)
Sales 2017 51,9 M
EBIT 2017 -59,4 M
Net income 2017 -62,4 M
Finance 2017 30,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 4,36x
EV / Sales 2018 3,95x
Capitalization 256 M
Chart GENMARK DIAGNOSTICS, INC
Duration : Period :
GenMark Diagnostics, Inc Technical Analysis Chart | GNMK | US3723091043 | 4-Traders
Technical analysis trends GENMARK DIAGNOSTICS, INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 11,0 $
Spread / Average Target 135%
EPS Revisions
Managers
NameTitle
Hany Massarany President, Chief Executive Officer & Director
James Charles Fox Chairman
Brian Mitchell Senior Vice President-Operations
Scott Mendel CFO & Principal Accounting Office
Jon Faiz Kayyem Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMARK DIAGNOSTICS, INC12.23%256
THERMO FISHER SCIENTIFIC10.69%83 835
DANAHER7.08%69 136
INTUITIVE SURGICAL14.82%46 953
ROYAL PHILIPS4.63%38 112
BOSTON SCIENTIFIC CORPORATION10.77%37 708